Strategic Insight into the Global Women’s Healthcare Market, 2017

Opportunities in Point-of-care (POC) Diagnostics for Cardiology and Oncology, along with Wearables, Stand out in the Market
Share this:
Published: 20 Dec 2017

Across the world, women typically live longer than men. The reason behind the difference between male and female life expectancy is unclear but could be explained through biological, environmental, and behavioral factors. Because women typically outlive men, they are more likely to suffer from ill health and other age-related diseases. Women’s healthcare, especially in underdeveloped regions, remains largely confined to reproductive matters, particularly maternal health. Attention to other significant women’s health issues, such as oncology, reproductive health, and urology, is growing rapidly. Overall, advancements in women’s health diagnostic products are intense, and diagnostic technologies have been subjected to rapid change. Currently, women’s health diagnostic products are being targeted at markets outside of traditional hospitals or clinical laboratories. The demand for home healthcare services in women’s health is facing a steady increase; however, at the same time, there is pressure to lower costs and maintain the high quality of the care delivered at home. Continuous improvements in technology are bringing about a number of new diagnostic tests that consolidate high levels of accuracy with rapid, easy-to-use product designs. Women’s health is a prominent medical imaging sector into which various participants are venturing. Cardiovascular disease (CVD), which includes stroke and coronary heart disease (CHD), is the leading cause of death and disability in women. The onset of CHD in women is delayed by about 10 years because of the presence of estrogen prior to menopause. The rising global burden of CVD and increasing patient awareness of health monitoring are currently driving the growth of the cardiovascular diagnostic market. The increasing popularity of patient-friendly diagnostics has opened up several opportunities for advanced cardiovascular devices. At 3%, breast cancer is one of the leading causes of death in women worldwide; about 1 in 12 women will likely develop breast cancer at some point in her life. Risk factors include hormonal fluctuations, age, and genetic predisposition. Overweight women are considered to be at greater risk for developing breast cancer because with increased weight, the body produces greater amounts of estrogen. Similar to estrogen from hormone replacement therapy (HRT) increasing the risk of breast cancer, high amounts of estrogen produced before menopause increase the risk of breast cancer as well. With the growing number of urological conditions, including nephrolithiasis, commonly known as kidney stones; stress incontinence; and menorrhagia, several market participants are developing POCT devices for easy and accurate home testing for urinalysis. In addition, because of fast evolving women’s health and pregnancy care, the market for prenatal genetic tests has grown quickly, with the development of new and upgraded diagnostic tests and screening methods. This strategic research service provides key growth drivers and opportunities in clinical diagnostics and medical devices in the women's diagnostics market. Key Questions This Study Will Answer: Why should companies consider investing in the women’s healthcare market? What are the key growth opportunities in clinical diagnostics and medical devices related to women’s healthcare? What are the key emerging technologies and growth drivers that companies should focus on to remain relevant and competitive in this market?



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..